Pooled data from all eligible studies indicated that the TNF-α rs1800629 polymorphism was associated with cervical cancer risk in overall population under four genetic models i.e., allele (A vs. G: OR = 1.277, 95% CI = 1.104-1.477, P = 0.001), homozygote (AA vs. GG: OR = 1.333, 95% CI = 1.062-1.674, P = 0.013), heterozygote (AG vs. GG: OR = 1.307, 95% CI = 1.064-1.605, P = 0.011), and dominant (AA+AG vs. GG: OR = 1.324, 95% CI = 1.104-1.587, P = 0.002). This evidence concerns the gene TNF and cervical cancer.